Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014955
Abstract: Röth and colleagues present results of a phase 3 trial of the C1s classical complement pathway inhibitor sutimlimab for the treatment of patients with cold agglutinin disease (CAD) who did not receive a transfusion within… read more here.
Keywords: patients cold; agglutinin disease; sutimlimab; trial ... See more keywords